We performed reprogramming at 7 days post-stroke in order to preferentially target cortical astrocytes and not neural stem cells that also express GFAP [67,68,69,70], as this is a time we have previously demonstrated a rapid decline in the number of migratory neural stem cells present in the cortex by this time point [71]. The gene discussed is GFAP; the disease is stroke disorder.